BioSpace News Archive

BioVaxys Technology Corp. announced that the Ontario Securities Commission, as the Company’s principal regulator, on February 29, 2024, granted the Company’s previously announced application for the imposition of a management cease trade order under National Policy 12-203 – Management Cease Trade Orders.

BioVie Inc. announced the closing of its previously announced best efforts public offering of 15,000,000 shares of its common stock, pre-funded warrants to purchase 6,000,000 shares of its common stock and warrants to purchase up to 10,500,000 shares of common stock at a combined public offering price of $1.00 per share and associated Common Warrant.

Avinger, Inc. announced a new strategic partnership with Zylox-Tonbridge Medical Technology Co., Ltd., a leading medical device company in the neuro- and peripheral-vascular interventional market in China.

Rakuten Medical, Inc. announced the completion of a $119 million Series E preferred stock financing, including $45 million in new capital and the conversion of $74 million of convertible promissory notes with accrued interest.

Innovent Biologics, Inc. announced that the results of two clinical studies of IBI311,a Phase I trial in healthy subjects and a Phase II trial in patients with thyroid eye disease, in the form of oral presentation at the 39th Asia Pacific Academy of Ophthalmology Congress and the 21st International Congress of Endocrinology, respectively.

REGENXBIO Inc. announced the pricing of an underwritten upsized public offering of 4,565,260 shares of its common stock at the price of $23.00 per share and 1,521,740 pre-funded warrants at a price of $22.9999 per warrant, in each case before underwriting discounts and commissions.

Avalyn Pharma Inc. today announced that Lyn Baranowski, chief executive officer of Avalyn, and members of management will participate in the Leerink Partners Global Biopharma Conference.

Apnimed, Inc. today announced the company will participate in the Leerink Partners Global Biopharma Conference taking place in Miami on March 11-13, 2024.

Ventyx Biosciences, Inc. today announced that Company executives will participate in the following upcoming investor conferences.

Werewolf Therapeutics, Inc. today announced that Daniel J. Hicklin, Ph.D., President and Chief Executive Officer of Werewolf, and Randi Isaacs, M.D., Chief Medical Officer of Werewolf, will participate in a fireside chat at 9:20 AM ET on March 13, 2024, at the Leerink Partners Global Biopharma Conference, taking place March 11-13, 2024, in Miami, Florida.